ClinicalTrials.gg
RecruitingNCT05806099Updated Nov 20, 2024

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

A Phase 1/2 interventional study of MBS303 in Non-Hodgkin's Lymphoma, sponsored by Beijing Mabworks Biotech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Beijing Mabworks Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
44th of 183
132 · median 58
Started
2023
with 22 others
Phase 1/2
42 of 196
27 open now
Primary completion
2025-11
later than 35 of 109 live
Registered
135th of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 44th largest by planned enrollment of the 183 interventional ones that give a count, is one of 23 that started in 2023, is one of 42 in phase 1/2, reaches primary completion later than 35 of the 109 other live ones, and was the 135th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide written and to comply with the study protocol.
  2. Adult patients, ≥18 years of age;
  3. CD20+ B-cell Non-Hodgkin Lymphoma who have after or failed to respond to at least one prior treatment regimen with an anti-CD20 monoclonal antibody and for whom there is no available therapy expected to improve survival;
  4. (ECOG) performance status of 0 or 1;
  5. ≥3 months;
  6. , defined as at lease one bi-dimensionally measurable nodal lesion, defined as >1.5 cm in its longest dimension, or at least one bi-dimensionally measureable extranodal lesion, defined as >1.0 cm in its longest dimension
  7. Adequate hematologic, hepatic, and renal function.

Exclusion criteria

Exclusion Criteria:

  1. Chronic lymphoblastic leukemia, Burkitt lymphoma or lymphoplasmacytic lymphom;
  2. History of central nervous system (CNS) lymphoma or other CNS disease;
  3. Participants with known active infection, including bacterial, viral, parasite, mycobacterial, or other infections (excluding nail bed fungal infections);
  4. Surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, tumor embolization, or other antitumor therapy within 28 days prior to the first MBS303;
  5. Active or suspected diseases;
  6. Known severe allergic reaction or/and infusion reaction to monoclonal antibody;
  7. Evidence of significant, uncontrolled concomitant disease;
  8. Major surgery within 28 days prior to the first MBS303 administration or expected to undergo major surgery during the study treatment;
  9. History of another invasive malignant tumors in past 3 years;
  10. Participant with history of confirmed progressive multifocal leukoencephalopathy (PML);
  11. Severe hemorrhagic diseases such as hemophilia A, hemophilia B, vascular hemophilia, or spontaneous bleeding requiring blood transfusion or other medical intervention;
  12. Infection with (HIV), or (including HBsAg, HBcAb positive with abnormal HBV DNA or HCV RNA);
  13. Pregnant or lactating women; Females of (FCBP) must agree to use two reliable forms of simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) while participating in the study; 2) for at least 12 months after discontinuation of all study treatments.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    MBS303

    Drug: MBS303

Interventions

  • DrugMBS303

    Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg \~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7. Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7

06

What researchers measure

Primary outcomes

  1. Phase I:Percentage of Participants with Adverse Events (AEs)

    Percentage of Participants with AEs and SAEs Assessed by NCI CTCAE v5.0

    Time frame: From Baseline up to approximately 13 months

  2. Phase I:Incidence of Dose Limiting Toxicities (DLTs)

    Time frame: From Baseline up to 3 weeks

  3. Phase I:Maximum Tolerated Dose (MTD) of MBS303

    Time frame: From Baseline up to 3 weeks

  4. Phase I:Recommended Phase Ⅱ Dose (RP2D) of MBS303

    Time frame: From Baseline up to 4 years

  5. Phase Ⅱ :Antitumor activity as measured by the objective response rate (ORR)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Phase I and Ⅱ :Pharmacokinetics: AUC

    The area under the curve (AUC) of serum concentration of MBS303 after the administration

    Time frame: up to approximately 1 year

  2. Phase I and Ⅱ :Pharmacokinetics: t1/2

    Half-life (t1/2) of MBS303 after administration

    Time frame: up to approximately 1 year

  3. Phase I and Ⅱ :Pharmacokinetics: CL

    Clearance (CL) of MBS303 after administration

    Time frame: up to approximately 1 year

  4. Phase I and Ⅱ :Pharmacokinetics: Vd

    Volume of distribution (Vd) of MBS303 after administration

    Time frame: up to approximately 1 year

  5. Phase I and Ⅱ :Efficacy: Complete Response Rate (CRR) of MBS303 as Assessed Using Standard Criteria for NHL

    Time frame: Up to approximately 2 years

  6. Phase I and Ⅱ :Efficacy: Duration of Response (DOR) of MBS303 as Assessed Using Standard Criteria for NHL

    Time frame: Up to approximately 2 years

  7. Phase I and Ⅱ :Efficacy: Progression-Free Survival (PFS) of MBS303 as Assessed Using Standard Criteria for NHL

    Time frame: Up to approximately 2 years

  8. Phase I and Ⅱ :Efficacy: Overall Survival (OS) of MBS303

    Time frame: Up to approximately 2 years

  9. Phase I and Ⅱ :Immunogenicity: Anti-Drug Antibodies (ADA) to MBS303

    Time frame: Up to approximately 1 year

  10. Phase I :Efficacy: ORR

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Nov 2025, 29 months after the start.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 29 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Apr 10, 2023
StartActual
Jun 28, 2023
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2026
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05806099
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Apr 10, 2023
Start date
Jun 28, 2023
Primary completion
Nov 2025 (estimated)
Completion
Nov 2026 (estimated)
Last update
Nov 20, 2024

Study contacts

Yuqin Song, Doctor
Contact
SongYQ_VIP@163.com
8610-88196118

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion